Our Speakers



Our Speakers

Ann White
Ann White

Senior Principal Scientist, UCB Celltech

Anneli Anderson
Anneli Anderson

Scientific Project Manager, Nebion, Switzerland

Dr. Mark Creighton-Gutteridge
Dr. Mark Creighton-Gutteridge

Head of Discovery and New Technologies, Oncology Cell Therapy Unit, GlaxoSmithKline, UK

Dr. Matthias Friedrich
Dr. Matthias Friedrich

Scientific Director, Nonclinical Development AMGEN Research (Munich) GmbH

Liselotte Brix
Liselotte Brix

Co founderChief Scientific Officer

Immudex, USA

Prof. Angus Dalgleish
Prof. Angus Dalgleish

Professor of Oncology, Chair of oncology -Institute of Infection and Immunity St. George’s University of London, UK

Prof. Hardev Pandha
Prof. Hardev Pandha

Professor of Medical Oncology- Tumour Immunology University of Surrey, UK

Robert Boyd
Robert Boyd

UK Site Head and Scientific Director,Oxford BioTherapeutics

Robert Hawkins
Robert Hawkins

Professor & Medical Oncologist, University of Manchester

Sophia Karagiannis
Sophia Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy

King's College London

Stefan Glueck
Stefan Glueck

Vice President, Global Medical Affairs Solid Tumors, Immuno-Oncology and Early Assets, Clegene

Celgene

Eugene	Zhukovsky
Eugene Zhukovsky

CSO

Biomunex Pharmaceuticals

Jeanette	Leusen
Jeanette Leusen

Group Leader, Tumor Immunology

UMC Utrecht

Lindy Durrant
Lindy Durrant

Professor-Cancer Immunotherapy

The University of Nottingham

Matthias Peipp
Matthias Peipp

Professor, Group Leader

University of Kiel

Livija Deban
Livija Deban

VP Immunology and Oncology

Prokarium

Shailendra Singh (Shelly)
Shailendra Singh (Shelly)

Chief Operating Officer

MarketsandMarkets

Michelle Morrow
Michelle Morrow

Vice President, Preclinical and Translational Pharmacology

F-Star Biotechnology Ltd, UK

Kandeepan Ganeshaligam
Kandeepan Ganeshaligam

Executive Director, Oncology Therapeutic Area Head

Merck, USA

David Giljohann
David Giljohann

CEO

Exicure, USA

Thomas Valerius
Thomas Valerius

Professor-Department of stem cell and immunotherapy

Kiel Life Science, Germany

Alex Blyth
Alex Blyth

CEO

LIfT BioSciences, UK

Laura Kenny
Laura Kenny

Clinical Senior Lecturer, Medical Oncology

Imperial College of London, UK

Rob Allen
Rob Allen

Senior Director, Immunotherapy Programme

Asterias Biotherapeutics, UK

Michael Burnet
Michael Burnet

Managing Director

Synovo, Germany

Heinz Lubenau
Heinz Lubenau

Chief Operating Officer, Co-Founder

Vaximm, Germany

Zoe Johnson
Zoe Johnson

Head Translational Research & Early Development

iOnctura, Switzerland

Stephen Beers
Stephen Beers

Professor, Immunology and Immunotherapy

University of Southampton, UK

Lucia Pattarini
Lucia Pattarini

Project Manager, Immuno- Oncology

Servier, France

John Maudsley
John Maudsley

Chief Executive Officer

Cancer Vaccines Ltd

Will Arends
Will Arends

Chartered (UK) and European Patent Attorney

Marks & Clerk, UK

Daulet Satpayev
Daulet Satpayev

Senior Director, Discovery Research

Adicet Bio, USA

Andrew Sewell
Andrew Sewell

Professor, Division of Infection and Immunity

Cardiff University, UK

Lolke de Haan
Lolke de Haan

Senior Director R&D, Toxicology, Global Immuno-Oncology Nonclinical Safety Lead

ad MedImmune, UK

Emiliano Melandri
Emiliano Melandri

Global Product Manager Immunology

Miltenyi Biotech, UK

Louise Affleck
Louise Affleck

UK Team Leader

Cisbio, UK

Sebastien Tabruyn
Sebastien Tabruyn

Chief Scientific Officer

TransCure Bioservices, France

Renier Heijkants
Renier Heijkants

Scientist

APO-T, Netherlands


Loading...